Hi_老虎社区_美港股上老虎

JonC1997
2021-12-14

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-lin

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":607309717,"tweetId":"607309717","gmtCreate":1639483533659,"gmtModify":1639483534052,"author":{"id":3581841381174598,"idStr":"3581841381174598","authorId":3581841381174598,"authorIdStr":"3581841381174598","name":"JonC1997","avatar":"https://static.tigerbbs.com/3b36205562e7be603067005666045365","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hi</p></body></html>","htmlText":"<html><head></head><body><p>Hi</p></body></html>","text":"Hi","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607309717","repostId":1123768155,"repostType":4,"repost":{"id":"1123768155","pubTimestamp":1639483311,"share":"https://www.laohu8.com/m/news/1123768155?lang=&edition=full","pubTime":"2021-12-14 20:01","market":"us","language":"en","title":"Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1123768155","media":"Benzinga","summary":"Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-lin","content":"<p><b>Kite Pharma</b>, a&nbsp;<b>Gilead Science Inc</b>&nbsp;company,&nbsp;churned out more data&nbsp;for its CAR-T Yescarta in first-line lymphoma patients.</p>\n<ul>\n <li>The Company shared the data at the American Society of Hematology (ASH) Annual Meeting &amp; Exposition.</li>\n <li>In updated results from the Phase 2 ZUMA-12 study, Yescarta posted a 78% complete response rate among 37 patients with high-risk large B cell lymphoma at a median follow-up of 15.9 months.</li>\n <li>All median survival checkpoints hadn't been reached at a median of 15.9 months after infusion. Still, Kite floated 12-month outcomes estimates of 81% for durable responders, 73% for event-free survival, 75% for progression-free survival, and 91% for patients alive.</li>\n <li>On the safety front, grade 3 or higher cytokine release syndrome occurred in 8% of patients, and 23% experienced a Grade 3 or higher neurological event.</li>\n <li>There were no deaths tied to treatment with Yescarta, although one patient died from COVID-19.</li>\n <li>All but one CRS and neurological events were resolved through treatment by the data cutoff.</li>\n <li><b>Price Action:</b>&nbsp;GILD shares closed at $70.61&nbsp;on Monday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients.\n\nThe Company shared the data at the American Society of Hematology (ASH) Annual...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123768155","content_text":"Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients.\n\nThe Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition.\nIn updated results from the Phase 2 ZUMA-12 study, Yescarta posted a 78% complete response rate among 37 patients with high-risk large B cell lymphoma at a median follow-up of 15.9 months.\nAll median survival checkpoints hadn't been reached at a median of 15.9 months after infusion. Still, Kite floated 12-month outcomes estimates of 81% for durable responders, 73% for event-free survival, 75% for progression-free survival, and 91% for patients alive.\nOn the safety front, grade 3 or higher cytokine release syndrome occurred in 8% of patients, and 23% experienced a Grade 3 or higher neurological event.\nThere were no deaths tied to treatment with Yescarta, although one patient died from COVID-19.\nAll but one CRS and neurological events were resolved through treatment by the data cutoff.\nPrice Action: GILD shares closed at $70.61 on Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1437,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

评论（2）

热议股票